Sun Pharma has secured a two-year deferral on US tariffs for its innovative drugs by offering better pricing to Medicaid. While the company reported a strong 27% profit growth in Q1 FY27, investors are now tracking the financial impact of the upcoming $11.75 billion Organon acquisition and ongoing pressure in the US generics business.
Sun Pharmaceutical Industries has reached a significant agreement with the US government to defer Section 232 tariffs on its innovative drug portfolio for more than two years. This development resolves a regulatory challenge that could have impacted the company's cost structure in its largest market. As part of the arrangement, Sun Pharma has committed to extending Most Favoured Nation pricing to US Medicaid programs. While this ensures continued access to US markets without the burden of these specific tariffs, it involves a commitment to offer lower prices on certain products, which may impact profit margins in the US segment over time.
The company’s focus on specialty and innovative medicines continues to yield results, acting as a balance against slowing growth in its traditional US generics business. In the first quarter of fiscal year 2027, Sun Pharma reported a consolidated net profit rise of 27% year-on-year to ₹2,895 crore, while revenue grew by 10.1% to ₹151,836 million. Innovative medicines now contribute approximately 21.9% of the company's total sales, signaling that the shift toward higher-value products is gaining traction.
Looking ahead, the company is preparing for a major structural change through the acquisition of Organon assets. This $11.75 billion all-cash deal is expected to close in early 2027. The acquisition is designed to establish the company as a top-tier global player in biosimilars and women’s health. However, this expansion comes with significant financial implications. The transition from a cash-surplus position to an anticipated Net Debt/EBITDA ratio of around 2.3x by the time the deal closes is a point investors are watching closely. The company is also expanding its global footprint through a licensing deal with LIB Therapeutics for a cholesterol-lowering medication, further diversifying its pipeline outside of the US and China.
Despite these strategic moves, risks remain. The US generics market continues to face pricing pressure, which has historically been a key contributor to the company’s revenue. Investors may track whether the innovative drug portfolio can grow fast enough to offset these traditional challenges. Furthermore, the financial commitment to MFN pricing for Medicaid and the debt load associated with the Organon acquisition will be important monitorables for the company’s cash flow and balance sheet health in the coming quarters. The next significant update for shareholders will be the progress on the acquisition integration and the performance of newer drug launches as they reach scale in international markets.